low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia

Clicks: 215
ID: 198841
2017
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
It is difficult to predict musculoskeletal pain as a withdrawal syndrome following the discontinuation of imatinib (IM) in patients with chronic myeloid leukemia. We investigated a link between physical size and musculoskeletal pain following IM discontinuation. In total, seven out of 24 patients developed musculoskeletal pain after discontinuing IM. Those with symptoms had a significantly lower body weight (BW) and body mass index (BMI) than those without symptoms. While previous reports indicated that physical size is associated with the pharmacokinetics of IM, our current study suggests that lower BW and BMI may be associated with musculoskeletal pain following IM discontinuation.
Reference Key
katagiri2017leukemialow Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Seiichiro Katagiri;Tetsuzo Tauchi;Keiko Ando;Seiichi Okabe;Moritaka Gotoh;Kazuma Ohyashiki
Journal urology annals
Year 2017
DOI 10.1016/j.lrr.2017.04.002
URL
http://www.sciencedirect.com/science/article/pii/S2213048916300577
Keywords
body weight chronic myeloid leukemia musculoskeletal pain Oncology including cancer and carcinogens tumors

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.